We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-8.87%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.94B
AUM Growth
-$1.55B
Cap. Flow
-$1.01B
Cap. Flow %
-34.35%
Top 10 Hldgs %
43.7%
Holding
135
New
15
Increased
7
Reduced
68
Closed
31

Top Buys

Rank Stock Value
1
GLUE icon
Monte Rosa Therapeutics
GLUE
+$65.1M
2
BMEA icon
Biomea Fusion
BMEA
+$56M
3
JBIO
Jade Biosciences
JBIO
+$46.4M
4
RAIN
Rain Oncology Inc. Common Stock
RAIN
+$46M
5
AMAM
Ambrx Biopharma Inc
AMAM
+$42.4M

Top Sells

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$76.5M
2
APLS
Apellis Pharmaceuticals
APLS
+$52.4M
3
NVAX icon
Novavax
NVAX
+$45.3M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$43.6M
5
OMER icon
Omeros
OMER
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMV
101
DELISTED
IMV Inc. Common Shares
IMV
$507K 0.02%
23,437
– –
CEREW
102
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$278K 0.01%
19,316
-114,015
-86% -$572K
NUVB.WS
103
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$217K 0.01%
83,332
– –
OTLKW
104
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$130K ﹤0.01%
416,666
– –
ALLK
105
DELISTED
Allakos
ALLK
– –
-25,000
Closed -$2.87M
ARGX icon
106
argenx
ARGX
$54.8B
– –
-30,000
Closed -$8.26M
AXSM icon
107
Axsome Therapeutics
AXSM
$10.8B
– –
-200,000
Closed -$11.3M
BNTX icon
108
BioNTech
BNTX
$22.9B
– –
-100,000
Closed -$10.9M
CGEM icon
109
Cullinan Oncology
CGEM
$1.1B
– –
-150,000
Closed -$6.25M
FATE icon
110
Fate Therapeutics
FATE
$290M
– –
-10,000
Closed -$824K
FDMT icon
111
4D Molecular Therapeutics
FDMT
$552M
– –
-200,000
Closed -$8.68M
FHTX icon
112
Foghorn Therapeutics
FHTX
$327M
– –
-1,000,000
Closed -$13.2M
IMVT icon
113
Immunovant
IMVT
$8.2B
– –
-337,048
Closed -$5.41M
IRON icon
114
Disc Medicine
IRON
$2.97B
– –
-15,833
Closed -$6.44M
KALV
115
DELISTED
KalVista Pharmaceuticals
KALV
– –
-750,000
Closed -$19.3M
KNSA icon
116
Kiniksa Pharmaceuticals
KNSA
$5.97B
– –
-130,000
Closed -$2.41M
NKTR icon
117
Nektar Therapeutics
NKTR
$2.48B
– –
-1,333
Closed -$400K
NTLA icon
118
PUT
Intellia Therapeutics
NTLA
$1.57B
– –
-300,000
Closed -$24.1M
NUVB icon
119
Nuvation Bio
NUVB
$2.13B
– –
-234,445
Closed -$2.45M
NVAX icon
120
Novavax
NVAX
$1.27B
– –
-250,000
Closed -$45.3M
REPL icon
121
Replimune Group
REPL
$1.08B
– –
-125,000
Closed -$3.81M
SPY icon
122
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
– –
-1,000,000
Closed -$396M
SRPT icon
123
Sarepta Therapeutics
SRPT
$1.77B
– –
-70,000
Closed -$5.22M
TARA icon
124
Protara Therapeutics
TARA
$230M
– –
-350,000
Closed -$5.51M
TIL icon
125
Instil Bio
TIL
$49.4M
– –
-7,500
Closed -$3.76M
2 3 4
5
6

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.79% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Cormorant Asset Management held 135 positions worth $2.94B, down 34% from $4.49B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Cormorant Asset Management withdrew a net $1.01B in Q2 2021, closing 31 positions and reducing 68 holdings. Its most notable exit was Novavax, an estimated $45.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 75% a quarter earlier, followed by Financials.

Against the trend, Cormorant Asset Management opened a new position in Monte Rosa Therapeutics worth $69.5M.

  • Cormorant Asset Management's largest Q2 2021 buy was Monte Rosa Therapeutics: 3,193,973 shares worth $69.5M.
  • Cormorant Asset Management added most to Revolution Medicines in Q2 2021, an estimated $28.4M increase.
  • Cormorant Asset Management's biggest Q2 2021 reduction was C4 Therapeutics, cutting an estimated $76.5M.
  • Cormorant Asset Management fully exited Novavax in Q2 2021, selling an estimated $45.3M.
  • Cormorant Asset Management's ten largest holdings make up 44% of its $2.94B portfolio in Q2 2021.
  • Cormorant Asset Management opened 15 new positions and closed 31 in Q2 2021.
  • Cormorant Asset Management's portfolio value fell 34% quarter-over-quarter to $2.94B.

Based on Cormorant Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.